The new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement CellMax Life's planned slate of liquid biopsy assays for early cancer detection.
The database is intended to provide the research community with a resource of control cases to aid in the evaluation of variants of unknown significance in breast cancer.
Under the Color Family Testing Program, family members of patients who tested positive for a gene on Color's hereditary cancer test can be tested for $50.
A year after launching the test in the US, the company is making it available in more than 100 countries, partnering with distributors in Israel, Turkey, and Finland.
Under the terms of the deal, Color Genomics will integrate Kapa Biosystems' library construction reagents into its NGS workflow.
Dozens of government agencies, academic institutions, and a various public and private sector organizations have now committed to driving the initiative forward.
Diatherix and Color Genomics now carry both CLIA certification and CAP accreditation.
Researchers are hoping the 100,000-patient WISDOM study will lead to genetically informed breast cancer screening based on a woman's unique risk factors.
Color Genomics hopes its recently launched benefits program will enable a broader population to have access to breast and ovarian cancer risk testing.
The company offers a panel that analyzes 19 genes associated with breast and ovarian cancer, including BRCA1/2, for $249.
According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.
The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.
A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.
In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.